Cite
HARVARD Citation
Choueiri, T. et al. (n.d.). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet oncology. 17 (7), pp. 917-927. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Choueiri, T. et al. (n.d.). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet oncology. 17 (7), pp. 917-927. [Online].